Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
CIITA
CITA/NLRC5
Cancer
MHC class I
NLR proteins
Journal
Immunogenetics
ISSN: 1432-1211
Titre abrégé: Immunogenetics
Pays: United States
ID NLM: 0420404
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
21
08
2018
accepted:
10
01
2019
pubmed:
2
2
2019
medline:
10
8
2019
entrez:
2
2
2019
Statut:
ppublish
Résumé
Major histocompatibility complex (MHC) class I and class II molecules play critical roles in the activation of the adaptive immune system by presenting antigens to CD8+ and CD4+ T cells, respectively. Although it has been well known that CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, as a master regulator of MHC class II gene expression, the mechanism of MHC class I gene transactivation was unclear. Recently, another NLR protein, NLRC5 (NLR family, CARD domain-containing 5), was identified as an MHC class I transactivator (CITA). NLRC5 is a critical regulator for the transcriptional activation of MHC class I genes and other genes involved in the MHC class I antigen presentation pathway. CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells. Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
Identifiants
pubmed: 30706093
doi: 10.1007/s00251-019-01106-z
pii: 10.1007/s00251-019-01106-z
doi:
Substances chimiques
Histocompatibility Antigens Class I
0
Intracellular Signaling Peptides and Proteins
0
NLRC5 protein, human
0
Trans-Activators
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
273-282Références
Cell. 1994 Jan 28;76(2):287-99
pubmed: 8293464
Cell. 1993 Oct 8;75(1):135-46
pubmed: 8402893
Cell. 2002 Apr;109 Suppl:S21-33
pubmed: 11983150
Proc Natl Acad Sci U S A. 1983 Apr;80(7):1982-6
pubmed: 6572957
J Immunol. 2010 Feb 15;184(4):1990-2000
pubmed: 20061403
Front Immunol. 2011 Oct 04;2:48
pubmed: 22566838
Biofactors. 2016 Jul 8;42(4):349-57
pubmed: 27087581
Cell. 2014 Jul 31;158(3):506-21
pubmed: 25083866
J Exp Med. 2000 Mar 20;191(6):961-76
pubmed: 10727458
Immunity. 1999 Feb;10(2):163-71
pubmed: 10072069
J Biol Chem. 2012 Jul 13;287(29):24294-303
pubmed: 22645137
J Cell Biol. 2015 Dec 7;211(5):1025-40
pubmed: 26620909
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Immunol. 2010 Aug 1;185(3):1681-91
pubmed: 20610642
Genes Dev. 2000 May 1;14(9):1156-66
pubmed: 10809673
Int J Cancer. 2010 Jul 15;127(2):249-56
pubmed: 20178101
Oncoimmunology. 2018 Mar 26;7(7):e1445453
pubmed: 29900056
J Immunol. 2012 May 15;188(10):4951-8
pubmed: 22490869
Mol Cell Biol. 2000 Nov;20(22):8489-98
pubmed: 11046145
Immunity. 1997 May;6(5):601-11
pubmed: 9175838
Biochemistry. 2014 May 20;53(19):3106-17
pubmed: 24815518
Biochem Biophys Res Commun. 2012 Feb 24;418(4):786-91
pubmed: 22310711
J Immunol. 2001 Oct 1;167(7):3626-34
pubmed: 11564775
Mol Cell Biol. 2000 Aug;20(16):6051-61
pubmed: 10913187
J Biol Chem. 2010 Aug 20;285(34):26223-32
pubmed: 20538593
Cell. 1988 Jun 17;53(6):897-906
pubmed: 3133120
Genes Dev. 1995 May 1;9(9):1021-32
pubmed: 7744245
J Immunol. 1999 Aug 1;163(3):1428-34
pubmed: 10415043
J Immunol. 2012 Apr 15;188(8):3820-8
pubmed: 22412192
Int J Cancer. 2003 Mar 1;103(6):759-67
pubmed: 12516095
Microbes Infect. 2012 Jun;14(6):477-84
pubmed: 22209772
J Virol. 2015 Aug;89(15):7636-45
pubmed: 25972545
J Cell Biol. 2015 Dec 7;211(5):941-3
pubmed: 26620908
Proc Natl Acad Sci U S A. 2016 May 24;113(21):5999-6004
pubmed: 27162338
Immunity. 1997 May;6(5):591-600
pubmed: 9175837
J Immunol. 2011 Jan 15;186(2):994-1000
pubmed: 21148033
J Immunol. 1998 Sep 1;161(5):2276-83
pubmed: 9725221
J Exp Med. 1994 Oct 1;180(4):1367-74
pubmed: 7931070
J Immunol. 2011 Feb 1;186(3):1333-7
pubmed: 21191067
EMBO J. 1997 Mar 3;16(5):1045-55
pubmed: 9118943
PLoS Genet. 2015 Mar 26;11(3):e1005088
pubmed: 25811463
Nat Genet. 1998 Nov;20(3):273-7
pubmed: 9806546
J Biol Chem. 2007 Sep 7;282(36):26178-84
pubmed: 17623662
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13794-9
pubmed: 20639463
J Immunol. 1999 Sep 1;163(5):2425-31
pubmed: 10452977
Immunity. 1998 Oct;9(4):531-41
pubmed: 9806639
Immunity. 1999 Feb;10(2):153-62
pubmed: 10072068
J Immunol. 2001 Nov 1;167(9):5175-84
pubmed: 11673530
J Biol Chem. 2001 Jun 1;276(22):19089-93
pubmed: 11279191
Eur J Immunol. 2015 Mar;45(3):758-72
pubmed: 25404059
J Virol. 2017 Aug 10;91(17):
pubmed: 28615208
J Immunol. 2012 Jul 15;189(2):516-20
pubmed: 22711889
Cancer Immunol Immunother. 2002 Sep;51(7):389-96
pubmed: 12192539
Oncoimmunology. 2016 Mar 28;5(6):e1151593
pubmed: 27471621
Annu Rev Immunol. 2001;19:331-73
pubmed: 11244040
Science. 1999 Aug 27;285(5432):1402-5
pubmed: 10464099
Immunity. 1996 Feb;4(2):167-78
pubmed: 8624807
Nat Rev Genet. 2009 Aug;10(8):551-64
pubmed: 19597530
Trends Cancer. 2017 Jan;3(1):28-38
pubmed: 28718425
Immunity. 2018 Feb 20;48(2):271-285.e5
pubmed: 29466757
Cell. 2010 Apr 30;141(3):483-96
pubmed: 20434986
Cell Res. 2012 May;22(5):836-47
pubmed: 22491475
J Immunol. 2012 May 15;188(10):4940-50
pubmed: 22490867